News

Media:

National Public Radio (NPR)

Tech Nation with Moira Gunn

“Replacing Some Of Your DNA With New DNA That Works Better — and Stopping It At Will”

MeiraGTx CEO Zandy Forbes speaks with NPR’s Moira Gunn.

To learn about everything from our Phase 3 program in RPGR to our riboswitch gene regulation platform, listen to the interview.

November 1, 2022

Audio (59 mins)

Media:

Bloomberg Surveillance

Hosted by Francine Lacqua

“MeiraGTx CEO on Potential of Gene Therapy, Innovation”

Interview

April 7, 2022

Video (4:31)

Manufacturing

MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government, Micheál Martin

Public Event

Press Release

September 16, 2022

Clinical Pipeline: Salivary

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Clinical Program Update / Data Release

December 13, 2022

MeiraGTX at the European Society of Gene and Cell Therapy (ESGCT)

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress.

Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy.

October 4, 2022

Press Release  |  Scientific Posters

Clinical Pipeline: Ocular

X-Linked Retinitis Pigmentosa (XLRP)

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP).

Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which is actively dosing patients.

October 1, 2022

Press Release  |  Data Release

Media:

Euronews Next

“This Gene Therapy Company is Testing New Tech to ‘Switch Off’ Diabetes and Obesity With a Pill”

By Natalie Huet

Article

September 28, 2022